Find out if you have a Celebrex® lawsuit

A settlement with Pfizer, the manufacturer of Celebrex and Bextra, and our Celebrex and Bextra clients has been reached.  As a result, we are no longer accepting new Celebrex or Bextra claims.

Concerns for cardiovascular related Celebrex® side effects have been raised in the media again following new reports on the dangers of the Cox-2 Inhibitor family of drugs. On February 16, 2005, the FDA’s panel to evaluate the safety of these drugs featured testimony from Merck & Co. who told FDA advisers that research linking its withdrawn Vioxx to heart attacks and strokes may apply to the entire class of painkillers, including Celebrex® and Bextra®. This follows earlier news that Pfizer halted a Celebrex® cancer study due to the cardiovascular side effects experienced by study participants.

According to statements made by CNN on December 17, 2004, Pfizer CEO Hank McKinnell cited new results from clinical trials that he called “unexpected,” and said the company was taking “immediate steps to fully understand the results and rapidly communicate new information to regulators, physicians and patients around the world.” To read more of the story…

Like the recently recalled Merck arthritis drug Vioxx®, Celebrex® is a member of the COX-2 inhibitor family.

Celebrex® (celecoxib) was approved by the FDA on December 29, 1999. The drug is made by Pfizer for the treatment of pain and tenderness associated with osteoarthritis and adult rheumatoid arthritis. Celebrex has been prescribed to 27 million Americans and is the world’s most widely prescribed arthritis drug, according to Pfizer.

If you suspect that Celebrex® has caused side effects or injured you, you should call our injury lawyers in Arizona now at 1-800-THE-EAGLE (1-800-843-3245) or SUBMIT A SHORT AND SIMPLE CASE FORM HERE.

Let Us Help You Seek Justice

Email us information about your potential claim, or give us a call 24/7 at 1-800-THE-EAGLE (1-800-843-3245) for a free, no obligation consultation.
  • I agree that I am not a client of Goldberg & Osborne for this matter unless I sign a written fee agreement with the Firm.

  • This field is for validation purposes and should be left unchanged.